Loading
Growing a patient's own cancer cells in a dish and testing drugs on them directly, instead of guessing from genetics.
Patient-derived organoids and short-term ex vivo cultures (SEngine PARIS, Cancertain, Xilis, Curesponse) expose live tumour cells to drug panels. Feasibility and correlation with response are established in colorectal, pancreatic, and ovarian cancer; randomised proof of benefit is pending. Complementary to genomics when no actionable mutation exists.
Fresh tumour tissue dissociated and cultured in matrix; viability read-outs per drug within 1-3 weeks.
Query for this technology: (TITLE:"functional precision medicine" OR ABSTRACT:"functional precision medicine" OR TITLE:"ex vivo drug sensitivity" OR ABSTRACT:"ex vivo drug sensitivity" OR TITLE:"drug sensitivity testing" OR ABSTRACT:"drug sensitivity testing") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Functional (ex vivo) drug testing, not a curated reading list.
Shares Certis Oncology Solutions, Zebrafish avatars for a drug answer within a week, Organoid, Biobanking and tissue procurement.
Shares Every drug screen includes standard reference compounds whose performance is published, A drug screen that only rewards killing sleeping cancer cells, A public atlas of drug-pair responses across a thousand patient-derived organoids, An open model bank for the rare tumours nobody has models for.
Shares Every resistance mechanism found in a patient must be rebuilt in the laboratory, An open atlas of collateral sensitivity for every approved targeted drug, Every drug screen includes standard reference compounds whose performance is published, A drug screen that only rewards killing sleeping cancer cells.
Shares Every resistance mechanism found in a patient must be rebuilt in the laboratory, Test drugs on freshly cut slices of the patient's own tumour, Zebrafish avatars for a drug answer within a week, Grow tumour organoids together with the patient's own immune cells.
Shares A funded organoid and PDX panel as the go/no-go gate before IND-enabling money, A public atlas of drug-pair responses across a thousand patient-derived organoids, An open model bank for the rare tumours nobody has models for, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico.
Shares Every drug screen includes standard reference compounds whose performance is published, A public atlas of drug-pair responses across a thousand patient-derived organoids, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Preclinical results do not reproduce.
Shares Origin Bio, Valius Sciences, A bone marrow niche on a chip to study human dormancy, Test drugs on freshly cut slices of the patient's own tumour.
Shares Run the mouse or organoid trial at the same time as the human trial, Test drugs on the patient's own cancer cells when there is no trial to join, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Patient-derived organoids.
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
A Bioconductor package for analysing large pharmacogenomic datasets such as GDSC and CCLE, from the Haibe-Kains lab.
An R package that predicts drug response in patient tumours from cell-line screening data.
Calculates and visualises drug combination synergy from dose-response matrices.
A 100 million cell single-cell perturbation atlas of 1,100 drugs across 50 cancer cell lines from Vevo Therapeutics, openly released.